AU3757999A - Adenosine a1 receptor antagonist containing composition and method for restoringdiuretic and renal function - Google Patents

Adenosine a1 receptor antagonist containing composition and method for restoringdiuretic and renal function

Info

Publication number
AU3757999A
AU3757999A AU37579/99A AU3757999A AU3757999A AU 3757999 A AU3757999 A AU 3757999A AU 37579/99 A AU37579/99 A AU 37579/99A AU 3757999 A AU3757999 A AU 3757999A AU 3757999 A AU3757999 A AU 3757999A
Authority
AU
Australia
Prior art keywords
adenosine
restoringdiuretic
renal function
receptor antagonist
containing composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU37579/99A
Other languages
English (en)
Inventor
Evan Beckman
Glenn Smits
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of AU3757999A publication Critical patent/AU3757999A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU37579/99A 1998-04-24 1999-04-23 Adenosine a1 receptor antagonist containing composition and method for restoringdiuretic and renal function Abandoned AU3757999A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8302298P 1998-04-24 1998-04-24
US60083022 1998-04-24
US8363898P 1998-04-30 1998-04-30
US60083638 1998-04-30
PCT/US1999/008879 WO1999055339A1 (en) 1998-04-24 1999-04-23 Adenosine a1 receptor antagonist containing composition and method for restoring diuretic and renal function

Publications (1)

Publication Number Publication Date
AU3757999A true AU3757999A (en) 1999-11-16

Family

ID=26768857

Family Applications (1)

Application Number Title Priority Date Filing Date
AU37579/99A Abandoned AU3757999A (en) 1998-04-24 1999-04-23 Adenosine a1 receptor antagonist containing composition and method for restoringdiuretic and renal function

Country Status (8)

Country Link
EP (1) EP0994711B1 (cg-RX-API-DMAC7.html)
JP (2) JP2002506463A (cg-RX-API-DMAC7.html)
AT (1) ATE252905T1 (cg-RX-API-DMAC7.html)
AU (1) AU3757999A (cg-RX-API-DMAC7.html)
CA (1) CA2295101C (cg-RX-API-DMAC7.html)
DE (1) DE69912375T2 (cg-RX-API-DMAC7.html)
ES (1) ES2211079T3 (cg-RX-API-DMAC7.html)
WO (1) WO1999055339A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0970696A1 (en) * 1998-05-05 2000-01-12 Kyowa Hakko Kogyo Co., Ltd. Combination of loop diuretics with adenosine A1-receptor antagonists
NZ527917A (en) 1999-11-12 2005-03-24 Biogen Inc Polycycoalkylpurines as adenosine receptor antagonists
CN1859913A (zh) * 2003-04-25 2006-11-08 美国诺华卡迪亚公司 改善肾功能损伤个体多尿症的方法
EP1932529A1 (en) * 2003-04-25 2008-06-18 Novacardia, Inc. Method of improved diuresis in individuals with impaired renal function
US20050239759A1 (en) * 2004-04-16 2005-10-27 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist and an aldosterone inhibitor
WO2018153898A1 (de) * 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit mineralocorticoid-rezeptor-antagonisten

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB998971A (en) * 1961-09-21 1965-07-21 Societé Civile Nova Improvements in or relating to medicines having a diuretic action
DE3305935C2 (de) * 1983-02-21 1985-05-30 Medice Chem.-Pharm. Fabrik Pütter GmbH & Co KG, 5860 Iserlohn Kaliumneutrales Saluretikum mit antihypertensiver Wirkung
JPS61271226A (ja) * 1985-05-24 1986-12-01 Chemo Sero Therapeut Res Inst 利尿剤
JPH01254664A (ja) * 1988-04-04 1989-10-11 Daiichi Rajio Isotope Kenkyusho:Kk 新規ピリジニウム−テクネチウム９９ｍ錯体
JP2689023B2 (ja) * 1990-08-17 1997-12-10 バクスター、インターナショナル、インコーポレイテッド ヘモグロビンオリゴマーに基づく組成物及びその製造方法
DE4238367A1 (de) * 1992-11-13 1994-05-19 Boehringer Ingelheim Kg Diuretisches Mittel
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
US5726156A (en) * 1995-03-06 1998-03-10 Trega Biosciences, Inc. Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels

Also Published As

Publication number Publication date
EP0994711A1 (en) 2000-04-26
CA2295101A1 (en) 1999-11-04
DE69912375T2 (de) 2004-08-19
ES2211079T3 (es) 2004-07-01
JP2009102399A (ja) 2009-05-14
ATE252905T1 (de) 2003-11-15
DE69912375D1 (de) 2003-12-04
JP2002506463A (ja) 2002-02-26
WO1999055339A1 (en) 1999-11-04
WO1999055339A8 (en) 1999-12-29
EP0994711B1 (en) 2003-10-29
CA2295101C (en) 2009-06-30

Similar Documents

Publication Publication Date Title
AU5640199A (en) 4-quinolinemethanol derivatives as purine receptor antagonists (i)
AU1772300A (en) Glucagon antagonists/inverse agonists
AU4091696A (en) Estrogen agonists/antagonists
IS5294A (is) 4-Amínópýrról (3,2-d) pýrimidín sem mótlyf fyrir taugapeptíð Y viðtaka
AU2455199A (en) Compositions and methods for regulated secretion from neuroendocrine cell lines
AU1918299A (en) Substituted quinoxaline derivatives as interleukin-8 receptor antagonists
AU5460598A (en) Pharmaceutical compositions containing vanilloid agonists in combination with vanilloid antagonists
AU5469096A (en) Pyrimidinedione, pyrimidinetrione, triazinedione, tetrahydroquinazolinedione derivatives as alpha1 adrenergic receptor antagonists
AU2697897A (en) Indole derivatives useful as endothelin receptor antagonists
ZA974234B (en) Adhesion receptor antagonists.
AU4746297A (en) Vitronectin receptor antagonists
WO2004017104A3 (en) Retroreflective aerosol coating composition and methods of making and using thereof
ZA9810685B (en) Thrombin receptor antagonists.
AUPP380498A0 (en) Egf receptor agonists and antagonists
AU4851999A (en) Novel benzimidazoles as corticotropin release factor antagonists
AU2095099A (en) Phthalimide-piperidine, -pyrrolidine and -azepine derivatives, their preparationand their use as muscarinic receptor (ant-)agonists
AU1403099A (en) Alpha-1a adrenergic receptor antagonists
WO1999055339A8 (en) Adenosine a1 receptor antagonist containing composition and method for restoring diuretic and renal function
AU6263996A (en) Method for screening for receptor agonists and antagonists
AU9512298A (en) Beta3-adrenoreceptor agonists, agonist compositions and methods of using
AU1100300A (en) Piperidyloxadiazoles as dopamine receptor antagonists
AU4980999A (en) A3 adenosine receptor antagonists
AU8370498A (en) Novel pyrimidin derivatives
AU1356299A (en) New compounds which are p2-purinoceptor 7-transmembrane (tm) g-protein coupled receptor antagonists
AU3611099A (en) Oxindole derivatives used as neurokinin receptor antagonists

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase